Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Biomarker, Safety, and Pharmacokinetic Study of Bapineuzumab (AAB-001) Administered Subcutaneously at Monthly Intervals in Subjects With Mild to Moderate Alzheimer's Disease

NCT01254773 is registered in ClinicalTrials.gov with JANSSEN Alzheimer Immunotherapy Research & Development, LLC as lead sponsor.

NCT NCT01254773
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01254773 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Biomarker, Safety, and Pharmacokinetic Study of Bapineuzumab (AAB-001) Administered Subcutaneously at Monthly Intervals in Subjects With Mild to Moderate Alzheimer's Disease
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2010
Completion date
March 31, 2013
Enrollment
146 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease